Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/22/2019 |
| Start Date: | July 2010 |
| End Date: | December 2019 |
The investigators have characterized in preclinical Non-Small Cell Lung Cancer (NSCLC) models
the proteomic expression profile associated with exposure to Aurora and Polo-like kinase
inhibitors. The identification of proteomic expression patterns in patients with NSCLC would
be an important step in defining the possible role of these agents as potential targeted
therapies for this clinically important disease. This study proposes to evaluate resected
non-small cell lung cancer specimens for these proteomic expression profiles.
the proteomic expression profile associated with exposure to Aurora and Polo-like kinase
inhibitors. The identification of proteomic expression patterns in patients with NSCLC would
be an important step in defining the possible role of these agents as potential targeted
therapies for this clinically important disease. This study proposes to evaluate resected
non-small cell lung cancer specimens for these proteomic expression profiles.
Inclusion Criteria:
- Subjects undergoing or who have undergone thoracic surgery for presumed lung cancer
- Wedge resection, lobectomy, bilobectomy, segmentectomy and pneumonectomy thoracic
surgical operations are permitted.
- Age ≥ 18 years.
- Subject meets criteria for thoracic surgery as determined by the thoracic surgeon.
- Able to provide written informed consent.
Exclusion Criteria:
- Subjects undergoing or who have undergone thoracic surgery for metastatic disease from
other primary sources such as colorectal cancer, sarcoma, melanoma, breast cancer,
bladder cancer, prostate cancer, esophageal cancer, pancreatic cancer, or gastric
cancer will be excluded.
- Subjects who have received prior preoperative lung cancer anticancer therapy will be
excluded.
We found this trial at
1
site
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
Click here to add this to my saved trials
